European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies-Reference-Cited by-同舟云学术

European Network of Gynaecological Oncological Trial Groups' Requirements for Trials Between Academic Groups and Pharmaceutical Companies

Published:2010-04 Issue:3 Volume:20 Page:476-478
ISSN:1048-891X
Container-title:International Journal of Gynecological Cancer
language:en
Short-container-title:International Journal of Gynecological Cancer

Author:

Vergote Ignace,Pujade-Lauraine Eric,Pignata Sandro,Kristensen Gunnar B.,Ledermann Jonathan,Casado Antonio,Sehouli Jalid,Mirza Mansoor,Fossati Roldano,Marth Christian,Creutzberg Carine,Del Campo Jose,Siddiqui Nadeem,Calvert Paula,Bamias Aris,Tulunay Gokhan,van der Zee Ate G.J.,du Bois Andreas

Publisher

BMJ

Subject

Obstetrics and Gynecology,Oncology

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dynamics of clonal hematopoiesis under DNA-damaging treatment in patients with ovarian cancer;Leukemia;2024-04-18

2. Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial;International Journal of Gynecologic Cancer;2023-12-21

3. Oral Selinexor as Maintenance Therapy After First-Line Chemotherapy for Advanced or Recurrent Endometrial Cancer;Journal of Clinical Oncology;2023-12-10

4. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial;Annals of Oncology;2023-12

5. Atezolizumab Combined With Bevacizumab and Platinum-Based Therapy for Platinum-Sensitive Ovarian Cancer: Placebo-Controlled Randomized Phase III ATALANTE/ENGOT-ov29 Trial;Journal of Clinical Oncology;2023-10-20